Investment in biomanufacturing across the USA has recorded a sharp rise, with pledged capital increasing by nearly 20 percent since 2024, according to a recent industry report. The surge positions biomanufacturing as one of the fastest-growing segments within the country’s advanced manufacturing landscape.

Biomanufacturing has outperformed other major manufacturing sectors in terms of new investment commitments, including automotive and high-technology manufacturing. Over the past two years, companies have announced close to USD 50 billion in new biomanufacturing facility investments, representing a significant jump compared to capital spending between 2020 and 2023.

The Northeast and Southern regions of the USA have emerged as leading destinations for new biomanufacturing projects. The Northeast alone has attracted nearly USD 12 billion in announced investments, while established life sciences hubs such as Boston, Philadelphia, San Diego, the Bay Area and North Carolina’s Research Triangle continue to see strong expansion activity. Several metro areas in North Carolina have also been ranked among the most competitive locations for biologics and advanced therapy manufacturing.

The report highlights that policy support for domestic manufacturing, supply chain resilience initiatives and increased demand for biologics and advanced therapies are key drivers behind the investment boom. Pharmaceutical and biotechnology companies are increasingly prioritizing domestic production capacity to ensure long-term supply security and regulatory compliance.

Despite the positive investment outlook, workforce availability remains a challenge. Biomanufacturing facilities require highly specialized technical talent, and shortages in areas such as cell and gene therapy manufacturing skills continue to impact expansion timelines.

Another notable trend is the growing need for specialized cold storage and temperature-controlled infrastructure alongside manufacturing sites. As biologics production scales up, companies are investing in expanded refrigerated storage capabilities to support complex manufacturing and distribution requirements.

Overall, the continued influx of capital is expected to strengthen the USA’s position as a global biomanufacturing hub and support long-term growth in advanced therapeutics manufacturing.